1-9 of 9
Heather Schneider
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Results of a Phase I/II Study of Tagraxofusp in Combination with Decitabine for Patients with Myelodysplastic/Myeloproliferative Neoplasms and Higher Risk Myelodysplastic Syndromes

Mehmet Sevki Uyanik, Guillermo Garcia-Manero, Abhishek Maiti, Farhad Ravandi, Kelly S. Chien, Danielle Hammond, Alexandre Bazinet, Heather Schneider, Stephany Hendrickson, Sherry Pierce, Hagop M. Kantarjian, Naveen Pemmaraju, Guillermo Montalban-Bravo
Journal: Blood
Blood (2024) 144 (Supplement 1): 1842.
https://doi.org/10.1182/blood-2024-207503
Published: 2024
Journal Articles

Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents

Guillermo Montalban-Bravo, Elias Jabbour, Kelly S. Chien, Gautam Borthakur, Zeev Estrov, Tapan M. Kadia, Farhad Ravandi, Naveen Pemmaraju, Graciela Nogueras-Gonzalez, Heather Schneider, Rosmy John, Meghan Anne Meyer, Hagop M. Kantarjian, Guillermo Garcia-Manero, Xiao Qin DONG
Journal: Blood
Blood (2023) 142 (Supplement 1): 1873.
https://doi.org/10.1182/blood-2023-178110
Published: 2023
Journal Articles

Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms with FLT3 or CBL Mutations

Guillermo Montalban-Bravo, Elias Jabbour, Kelly S. Chien, Danielle E. Hammond, Nicholas J. Short, Farhad Ravandi, Marina Y. Konopleva, Gautam Borthakur, Naval Daver, Rashmi Kanagal-Shamanna, Wei Qiao, Xuelin Huang, Heather Schneider, Meghan Anne Meyer, Hagop M. Kantarjian, Guillermo Garcia-Manero
Journal: Blood
Blood (2023) 142 (Supplement 1): 3238.
https://doi.org/10.1182/blood-2023-178115
Published: 2023
Journal Articles

Results of a Phase II Study of Cladribine, Low Dose Cytarabine and Venetoclax, Alternating with Azacitidine and Venetoclax in Patients with Higher Risk Chronic Myelomonocytic Leukemia or Myelodysplastic Syndromes

Guillermo Montalban-Bravo, Nicholas J. Short, Kelly S. Chien, Yesid Alvarado Valero, Naval Daver, Gautam Borthakur, Mahesh Swaminathan, Abhishek Maiti, Danielle E. Hammond, Graciela Nogueras-Gonzalez, Xuelin Huang, Heather Schneider, Kristen Shelly, Tapan M. Kadia, Hagop M. Kantarjian, Guillermo Garcia-Manero
Journal: Blood
Blood (2023) 142 (Supplement 1): 1876.
https://doi.org/10.1182/blood-2023-178035
Published: 2023
Journal Articles

A Phase I/II Study of Venetoclax in Combination with 5-Azacytidine in Treatment-Naïve and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Alexandre Bazinet, Elias J. Jabbour, Hagop Kantarjian, Kelly S. Chien, Courtney D. DiNardo, Maro Ohanian, Naval Daver, Rashmi Kanagal-Shamanna, Tapan M. Kadia, Koichi Takahashi, Lucia Masarova, Nicholas J. Short, Yesid Alvarado, Philip A. Thompson, Guillermo Montalban-Bravo, Musa Yilmaz, Farhad Ravandi, Steven M. Kornblau, Naveen Pemmaraju, Heather Schneider, Bailey Mirabella, Kiran Naqvi, Guillermo Garcia-Manero
Journal: Blood
Blood (2021) 138 (Supplement 1): 535.
https://doi.org/10.1182/blood-2021-153086
Published: 2021
Journal Articles

A Phase I Study of the Combination of Venetoclax and Azacitidine in Relapse/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

Sai Prasad Prasad Desikan, Guillermo Montalban-Bravo, Maro Ohanian, Naval Daver, Musa Yilmaz, Marina Konopleva, Tapan M. Kadia, Sangeetha Venugopal, Heather Schneider, Kelly S. Chien, Rashmi Kanagal-Shamanna, Hagop Kantarjian, Guillermo Garcia-Manero
Journal: Blood
Blood (2021) 138 (Supplement 1): 3704.
https://doi.org/10.1182/blood-2021-153170
Published: 2021
Journal Articles

Updated Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents

Guillermo Montalban-Bravo, Elias J. Jabbour, Zeev E. Estrov, Tapan M. Kadia, Farhad Ravandi, Kelly S. Chien, Graciela M. Nogueras González, Xiao Qin Dong, Stefan Faderl, Heather Schneider, Rosmy B. John, Meghan Anne Meyer, Hagop Kantarjian, Guillermo Garcia-Manero
Journal: Blood
Blood (2021) 138 (Supplement 1): 3674.
https://doi.org/10.1182/blood-2021-151493
Published: 2021
Journal Articles

Initial Results of a Phase 1 Dose Escalation Study of CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) after Failure to Hypomethylating Agents

Guillermo Montalban Bravo, MD, Elias Jabbour, MD, Tapan M. Kadia, MD, Farhad Ravandi, MBBS, Zeev E. Estrov, MD, Kiran Naqvi, MD MPH, Koji Sasaki, MD, Kelly S. Chien, MD, Graciela M. Nogueras González, MPH, Xiao Qin Dong, Stefan Faderl, MD, Heather Schneider, BSN, RN, Rosmy B. John, MSN, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–3.
https://doi.org/10.1182/blood-2020-139942
Published: 2020
Journal Articles

Phase I Study of Ruxolitinib for Patients (Pts) with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Who Failed at Least One Line of Therapy

Yasmin Abaza, MD, Elias J. Jabbour, MD, Srdan Verstovsek, MD PhD, Zeev Estrov, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Tapan M. Kadia, MD, Naval Daver, MD, Courtney D DiNardo, MD, Carlos E. Bueso-Ramos, MD PhD, Juliana E. Hidalgo, MD, Heather Schneider, BSN, RN, Guillermo Montalban Bravo, MD, Ana Alfonso, MD, Yue Wei, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2016) 128 (22): 4318.
https://doi.org/10.1182/blood.V128.22.4318.4318
Published: 2016